AR058591A1 - Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido - Google Patents
Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolidoInfo
- Publication number
- AR058591A1 AR058591A1 ARP060105668A ARP060105668A AR058591A1 AR 058591 A1 AR058591 A1 AR 058591A1 AR P060105668 A ARP060105668 A AR P060105668A AR P060105668 A ARP060105668 A AR P060105668A AR 058591 A1 AR058591 A1 AR 058591A1
- Authority
- AR
- Argentina
- Prior art keywords
- microparticles
- tumors
- octreotide
- polymers
- pharmaceutically acceptable
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title abstract 5
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title abstract 4
- 108010016076 Octreotide Proteins 0.000 title abstract 4
- 229960002700 octreotide Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000011859 microparticle Substances 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000009311 VIPoma Diseases 0.000 abstract 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 2
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 208000019493 atypical carcinoid tumor Diseases 0.000 abstract 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 238000009115 maintenance therapy Methods 0.000 abstract 2
- 239000012074 organic phase Substances 0.000 abstract 2
- 239000003791 organic solvent mixture Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000026775 severe diarrhea Diseases 0.000 abstract 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 238000000935 solvent evaporation Methods 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526247A GB0526247D0 (en) | 2005-12-22 | 2005-12-22 | Organic compounds |
| EP06119086 | 2006-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058591A1 true AR058591A1 (es) | 2008-02-13 |
Family
ID=37772904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105668A AR058591A1 (es) | 2005-12-22 | 2006-12-20 | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US20090004283A1 (https=) |
| EP (3) | EP2359809B1 (https=) |
| JP (4) | JP2009520727A (https=) |
| KR (5) | KR101458728B1 (https=) |
| CN (1) | CN103251929A (https=) |
| AR (1) | AR058591A1 (https=) |
| AU (1) | AU2006328950B2 (https=) |
| BR (2) | BR122019027412B8 (https=) |
| CA (1) | CA2631811C (https=) |
| CL (1) | CL2018003398A1 (https=) |
| EC (1) | ECSP088560A (https=) |
| ES (2) | ES2755032T3 (https=) |
| IL (1) | IL191842A0 (https=) |
| IN (1) | IN2015DN03936A (https=) |
| MA (1) | MA30064B1 (https=) |
| NO (1) | NO20082988L (https=) |
| PE (1) | PE20071139A1 (https=) |
| PL (2) | PL2359809T3 (https=) |
| PT (2) | PT2359809T (https=) |
| RU (1) | RU2464972C2 (https=) |
| TW (2) | TWI469788B (https=) |
| WO (1) | WO2007071395A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5419169B2 (ja) | 2007-06-06 | 2014-02-19 | デビオファーム リサーチ アンド マニュファクチャリング ソシエテ アノニム | 微小粒子で構成される徐放性医薬組成物 |
| US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| ES2324009B1 (es) * | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| KR101921800B1 (ko) * | 2008-01-30 | 2018-11-23 | 노파르티스 아게 | 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제 |
| AU2013201877B2 (en) * | 2008-01-30 | 2015-01-29 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| KR101814186B1 (ko) * | 2008-09-17 | 2018-03-14 | 키아스마 인코포레이티드 | 약제학적 조성물 및 연관된 투여방법 |
| US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
| CA2750003A1 (en) * | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Controlled release systems from polymer blends |
| WO2012012546A2 (en) * | 2010-07-21 | 2012-01-26 | Allergan, Inc. | METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
| GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
| WO2012083026A1 (en) * | 2010-12-15 | 2012-06-21 | Evonik Degussa Corporation | Branched polyol polyesters, blends and pharmaceutical formulations comprising same |
| HUE046004T2 (hu) | 2011-04-25 | 2020-01-28 | Shan Dong Luye Pharm Co Ltd | Risperidon nyújtott hatóanyagleadású mikroszféra készítmény |
| CN102488619B (zh) * | 2011-12-05 | 2014-08-06 | 上海交通大学 | 连续生产艾塞那肽微球的装置及控制微球释放速度的方法 |
| WO2016084849A1 (ja) * | 2014-11-25 | 2016-06-02 | Cbc株式会社 | ヤヌス微粒子及びその製造方法 |
| WO2016126830A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
| JP6165356B2 (ja) * | 2015-06-26 | 2017-07-19 | オリンパス株式会社 | 内視鏡システム |
| US12396951B2 (en) * | 2016-12-27 | 2025-08-26 | Upexmed Co. Ltd. | Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| MX2022002980A (es) | 2019-09-16 | 2022-04-06 | Amgen Inc | Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos. |
| CN111214643A (zh) * | 2020-03-11 | 2020-06-02 | 苏州善湾生物医药科技有限公司 | 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用 |
| JP6852943B1 (ja) * | 2020-05-08 | 2021-03-31 | エム・テクニック株式会社 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
| KR102947969B1 (ko) * | 2020-05-08 | 2026-04-06 | 엠. 테크닉 가부시키가이샤 | 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
| KR102947972B1 (ko) * | 2020-05-08 | 2026-04-06 | 엠. 테크닉 가부시키가이샤 | 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE3062075D1 (en) | 1979-11-27 | 1983-03-24 | Sandoz Ag | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| US5470582A (en) * | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| KR100260632B1 (ko) * | 1992-12-28 | 2000-07-01 | 성재갑 | 이식형 소마토트로핀 조성물 |
| US5603960A (en) * | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US6447796B1 (en) * | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| WO1998027980A2 (en) * | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
| IL133105A (en) * | 1997-06-04 | 2004-09-27 | Debio Rech Pharma Sa | Implants for controlled release of pharmaceutically active principles and method for making same |
| ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
| KR100392501B1 (ko) * | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | 다중 에멀젼법에 의한 서방출성 미립구의 제조방법 |
| ES2292655T3 (es) * | 2002-03-15 | 2008-03-16 | Alrise Biosystems Gmbh | Microparticulas y procedimiento para su preparacion. |
| RU2355385C2 (ru) * | 2002-11-06 | 2009-05-20 | Алза Корпорейшн | Композиции пролонгированного действия с контролируемым высвобождением |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
| ES2600554T3 (es) * | 2003-07-18 | 2017-02-09 | Oakwood Laboratories L.L.C. | Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas |
| JP5165240B2 (ja) * | 2003-07-23 | 2013-03-21 | ピーアール ファーマシューティカルズ， インコーポレイテッド | 徐放組成物 |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| DE602005013244D1 (de) * | 2004-08-12 | 2009-04-23 | Quest Pharmaceutical Services | Pharmazeutische zusammensetzungen für die kontroll |
-
2006
- 2006-12-20 ES ES10175382T patent/ES2755032T3/es active Active
- 2006-12-20 PE PE2006001665A patent/PE20071139A1/es not_active Application Discontinuation
- 2006-12-20 US US12/158,345 patent/US20090004283A1/en not_active Abandoned
- 2006-12-20 KR KR1020137004517A patent/KR101458728B1/ko active Active
- 2006-12-20 WO PCT/EP2006/012313 patent/WO2007071395A1/en not_active Ceased
- 2006-12-20 AU AU2006328950A patent/AU2006328950B2/en active Active
- 2006-12-20 KR KR1020147031146A patent/KR20140133968A/ko not_active Ceased
- 2006-12-20 PT PT101753820T patent/PT2359809T/pt unknown
- 2006-12-20 KR KR1020137004518A patent/KR20130024987A/ko not_active Ceased
- 2006-12-20 EP EP10175382.0A patent/EP2359809B1/en active Active
- 2006-12-20 KR KR1020137004520A patent/KR20130024988A/ko not_active Ceased
- 2006-12-20 PL PL10175382T patent/PL2359809T3/pl unknown
- 2006-12-20 ES ES06841059.6T patent/ES2492641T3/es active Active
- 2006-12-20 BR BR122019027412A patent/BR122019027412B8/pt active IP Right Grant
- 2006-12-20 CN CN2013101523825A patent/CN103251929A/zh active Pending
- 2006-12-20 AR ARP060105668A patent/AR058591A1/es unknown
- 2006-12-20 RU RU2008129626/15A patent/RU2464972C2/ru active
- 2006-12-20 KR KR1020087014985A patent/KR101245919B1/ko active Active
- 2006-12-20 BR BRPI0620063A patent/BRPI0620063B8/pt active IP Right Grant
- 2006-12-20 EP EP06841059.6A patent/EP1968549B1/en active Active
- 2006-12-20 CA CA2631811A patent/CA2631811C/en active Active
- 2006-12-20 JP JP2008546248A patent/JP2009520727A/ja active Pending
- 2006-12-20 PT PT68410596T patent/PT1968549E/pt unknown
- 2006-12-20 IN IN3936DEN2015 patent/IN2015DN03936A/en unknown
- 2006-12-20 PL PL06841059T patent/PL1968549T3/pl unknown
- 2006-12-20 EP EP19188892.4A patent/EP3603623A1/en not_active Withdrawn
- 2006-12-21 TW TW95148218A patent/TWI469788B/zh active
- 2006-12-21 TW TW103107772A patent/TWI468172B/zh active
-
2008
- 2008-05-29 IL IL191842A patent/IL191842A0/en unknown
- 2008-06-18 MA MA31048A patent/MA30064B1/fr unknown
- 2008-06-19 EC EC2008008560A patent/ECSP088560A/es unknown
- 2008-07-02 NO NO20082988A patent/NO20082988L/no not_active Application Discontinuation
-
2013
- 2013-04-25 JP JP2013092845A patent/JP6239851B2/ja active Active
-
2014
- 2014-10-08 JP JP2014207464A patent/JP6178772B2/ja active Active
- 2014-10-16 US US14/516,016 patent/US20150037420A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/977,801 patent/US20160120935A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115579A patent/JP2016216467A/ja not_active Withdrawn
-
2018
- 2018-01-17 US US15/873,473 patent/US20180140662A1/en not_active Abandoned
- 2018-11-29 CL CL2018003398A patent/CL2018003398A1/es unknown
-
2020
- 2020-03-10 US US16/813,864 patent/US20200206306A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,014 patent/US20220296675A1/en not_active Abandoned
-
2024
- 2024-11-22 US US18/956,119 patent/US20250082718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058591A1 (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido | |
| Wang et al. | Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study | |
| US20200368250A1 (en) | Stable formulations for parenteral injection of small molecule drugs | |
| Simon-Yarza et al. | Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia | |
| ES2541908T3 (es) | Microesferas biodegradables de liberación prolongada y su procedimiento de preparación | |
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| JP2010511596A5 (https=) | ||
| BR112020005948A2 (pt) | distribuição intensificada de composições de epinefrina e pró-fármaco | |
| BR112012017435A2 (pt) | processo para a preparação de composições farmacêuticas para a liberação sustentada de análogos de somatostatina | |
| JP2012512147A5 (https=) | ||
| WO2016059592A1 (en) | Stable injectable composition of peptide drugs and process for its preparation | |
| CO2021016449A2 (es) | Composiciones terapéuticas estables en solventes polares aproticos y métodos de fabricación de las mismas | |
| HRP20200329T1 (hr) | Poboljšane formulacije levosimendana za intravensku primjenu u obliku infuzije ili injekcije i koncentrata infuzije | |
| US10314880B2 (en) | Composition comprising bortezomib | |
| US20210161917A1 (en) | Composition for subcutaneous injection, containing deoxycholic acid, and preparation method therefor | |
| Huang et al. | Combined use of borneol or menthol with labrasol promotes penetration of baicalin through rabbit cornea in vitro. | |
| CN101721370A (zh) | 戈舍瑞林缓释微球制剂及其制备方法、检测方法 | |
| CN102580056B (zh) | 一种含抗利尿成分的缓释注射剂及其制备方法 | |
| CN101797243B (zh) | 一种含有左旋多巴和冰片的组合物及其应用 | |
| CN103908659B (zh) | Lhrh类似物和齐考诺肽组合物缓释微球制剂及其制备方法 | |
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| ES2608339T3 (es) | Emulsión antitumoral a base de Lipiodol para el tratamiento del cáncer | |
| CN101797266B (zh) | 一种含有槲皮苷的药物组合物及用途 | |
| BR102013008990A2 (pt) | Composições farmacêuticas compreendendo kisspeptina ou seus derivados |